Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Drug Profile

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Alternative Names: C10; C9; C9A; CFAK-C10; CFAK-C4; CFAK-C9; CFAK-C9a; CFAK-Y15; Chloropyramine; Chloropyramine hydrochloride; FAK inhibitors - CureFAKtor; FAK technology platform - CureFAKtor; Y15

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureFAKtor Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Preclinical for Solid tumours and Pancreatic cancer in USA (PO)
  • 14 Nov 2011 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) ,,
  • 23 Jun 2011 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology (ECCO/ESMO-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top